Headshot of Ashley Juavinett.

Ashley Juavinett

Associate teaching professor of neurobiology
University of California, San Diego

Ashley Juavinett is associate teaching professor of neurobiology at the University of California, San Diego, where she also co-directs STARTneuro, a program funded by the National Institutes of Health’s Blueprint Enhancing Neuroscience Diversity through Undergraduate Research Education Experiences. Through her work and writing, she seeks to understand the best ways to train the next generation of neuroscientists. A significant part of this effort is building resources to make such training accessible and more effective.

Juavinett completed her Ph.D. with Edward Callaway at the Salk Institute for Biological Studies in San Diego, California, investigating the cell types and circuits underlying visual perception in mice. She then conducted postdoctoral research with Anne Churchland at Cold Spring Harbor Laboratory in New York, advancing ethological approaches to understanding behavior as well as cutting-edge ways of recording from freely moving animals.

Juavinett is the author of “So You Want to Be a Neuroscientist?” an accessible guide to the field for aspiring researchers, and she has previously written for the Simons Collaboration on the Global Brain.

Explore more from The Transmitter

Hand holding a vial of microplastics.

Measuring plastic in the brain: Improving, but incomplete

Meanwhile, researchers are publishing papers without “sufficient quality control,” says analytical chemist Dušan Materić.

By Amber Dance
18 September 2026 | 9 min read
Calendar with deadline.

Incredible shrinking grant deadlines at the BRAIN Initiative

“A month is crazy,” says one former recipient, referring to a new funding opportunity’s timeline.

By Brendan Borrell
17 September 2026 | 4 min read

Sylvia Fogel, reshaping U.S. autism research strategy

In a wide-ranging and provocative interview, the chair of the federal Interagency Autism Coordinating Committee shares her views on vaccines, regression, neuroimmune conditions and more.

By Brady Huggett
17 September 2026 | 1 min read